Substance guides

Marijuana and psychosis: What the research shows

Published October 5, 2025 · 7 min read · Updated April 2026

Reviewed for accuracy by licensed clinical professionals.

The relationship between cannabis and psychosis is one of the most studied and debated topics in addiction psychiatry. The evidence is nuanced.

What the research shows

Regular cannabis use increases the risk of developing psychotic disorders. The risk is dose-dependent: daily use of high-potency cannabis carries the highest risk. Early onset use (before age 15) significantly increases vulnerability. Family history of psychotic disorders amplifies risk.

How it may work

THC increases dopamine release in brain regions associated with psychosis. In genetically vulnerable individuals, this may trigger or accelerate the onset of psychotic disorders. CBD (another cannabis compound) may have antipsychotic properties, meaning high-THC/low-CBD products carry more risk.

The potency factor

Modern cannabis products are dramatically more potent than those studied in earlier research. THC concentrations in concentrates (dabs) reach 80-90%. The psychosis research from the 1990s may significantly underestimate current risk.

Who is most vulnerable

People with family history of schizophrenia or bipolar disorder. Adolescents (developing brain). People who experience anxiety or paranoia when using cannabis. Those who use daily and high-potency products.

Authoritative sources

This article references guidelines from: SAMHSA · NIDA · ASAM

Frequently asked questions

Can marijuana cause schizophrenia?

Cannabis does not cause schizophrenia in the general population, but it significantly increases risk in genetically vulnerable individuals and may accelerate onset.

Does everyone who smokes weed risk psychosis?

No. Risk is highest in genetically vulnerable individuals, early-onset users, daily users, and those using high-potency products.

Is CBD safer than THC for psychosis risk?

CBD may have antipsychotic properties. High-THC/low-CBD products carry more psychosis risk than balanced products.

Disclaimer: Informational only. Not medical advice. SAMHSA: 1-800-662-4357.